- Home
- MHUA vs TLPH Comparison
MHUA vs TLPH Comparison
Compare MHUA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHUA | TLPH |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.8M | 64.7M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MHUA | TLPH |
|---|---|---|
| Price | $7.61 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 16.4K | ★ 330.7K |
| Earning Date | 12-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 28.96 | N/A |
| Revenue | ★ $89,547,563.00 | $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,267.20 |
| P/E Ratio | $0.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.36 | $0.38 |
| 52 Week High | $67.70 | $1.57 |
Technical Indicators
Market Signals| Indicator | MHUA | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 39.86 |
| Support Level | $11.41 | $1.20 |
| Resistance Level | $14.98 | $1.25 |
| Average True Range (ATR) | 1.54 | 0.09 |
| MACD | 0.36 | -0.02 |
| Stochastic Oscillator | 47.21 | 10.00 |
Price Performance
Historical ComparisonAbout MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.